Insider Selling: InfuSystem Holdings, Inc. (NYSE:INFU) CEO Sells 20,000 Shares of Stock

InfuSystem Holdings, Inc. (NYSE:INFU) CEO Richard Dilorio sold 20,000 shares of the business’s stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $9.32, for a total value of $186,400.00. Following the completion of the transaction, the chief executive officer now directly owns 436,659 shares of the company’s stock, valued at approximately $4,069,661.88. This trade represents a 4.38 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Richard Dilorio also recently made the following trade(s):

• On Wednesday, November 27th, Richard Dilorio sold 5,398 shares of InfuSystem stock. The shares were sold at an average price of $8.87, for a total value of $47,880.26.

InfuSystem Trading Down 1.1 %

NYSE:INFU opened at $8.85 on Thursday. The company has a market capitalization of $188.19 million, a PE ratio of 147.50 and a beta of 1.45. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.59 and a current ratio of 1.98. The business’s 50-day moving average price is $7.29. InfuSystem Holdings, Inc. has a 1-year low of $5.74 and a 1-year high of $10.99.

Institutional Trading of InfuSystem

Hedge funds and other institutional investors have recently made changes to their positions in the company. BNP Paribas Financial Markets grew its holdings in shares of InfuSystem by 66.4% during the third quarter. BNP Paribas Financial Markets now owns 4,076 shares of the company’s stock worth $27,000 after purchasing an additional 1,626 shares during the last quarter. Williams & Novak LLC bought a new stake in shares of InfuSystem during the third quarter worth about $70,000. Connor Clark & Lunn Investment Management Ltd. bought a new stake in InfuSystem in the third quarter valued at approximately $87,000. Rhumbline Advisers boosted its holdings in InfuSystem by 13.8% in the second quarter. Rhumbline Advisers now owns 17,658 shares of the company’s stock valued at $121,000 after acquiring an additional 2,145 shares during the last quarter. Finally, Marshall Wace LLP bought a new stake in InfuSystem in the second quarter valued at approximately $131,000. 71.13% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts have commented on INFU shares. B. Riley started coverage on InfuSystem in a research note on Thursday, September 26th. They set a “buy” rating and a $13.00 target price for the company. StockNews.com raised InfuSystem from a “buy” rating to a “strong-buy” rating in a research note on Friday, November 8th.

InfuSystem Company Profile

InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.